Literature DB >> 1310619

The endothelial cell binding determinant of human factor IX resides in the gamma-carboxyglutamic acid domain.

J R Toomey1, K J Smith, H R Roberts, D W Stafford.   

Abstract

The blood coagulation factor IX(a) binds specifically to a site on endothelial cells with a Kd of 2.0-3.0 nM. A number of previous studies have attempted to define the region(s) of factor IX(a) that mediate this interaction. These studies suggested that there are two regions of factor IX(a), the gamma-carboxyglutamic acid (Gla) domain and the epidermal growth factor like (EGF-like) domains, that mediate high-affinity binding to endothelial cells. Recently, however, the participation of the EGF1 domain has been excluded from the interaction. This indicated that if there was an EGF component of factor IX contributing to the binding affinity, then it must be in the second EGF-like domain. In order to further evaluate this relationship, we performed competitive binding experiments between 125I plasma factor IX and a set of six chimeric proteins composed of portions of factor VII and factor IX. Our data suggest that the high-affinity interaction between factor IX and the endothelial cell binding site is mediated by the factor IX Gla domain and that the factor IX EGF domains are not involved in binding specificity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310619     DOI: 10.1021/bi00121a031

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B.

Authors:  J Y Chang; D M Monroe; D W Stafford; K M Brinkhous; H R Roberts
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

2.  Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.

Authors:  Brian Cooley; William Funkhouser; Dougald Monroe; Ashley Ezzell; David M Mann; Feng-Chang Lin; Paul E Monahan; Darrel W Stafford
Journal:  Blood       Date:  2016-04-22       Impact factor: 22.113

3.  Evidence of clinically significant extravascular stores of factor IX.

Authors:  D Feng; K A Stafford; G J Broze; D W Stafford
Journal:  J Thromb Haemost       Date:  2013-12       Impact factor: 5.824

4.  Highly conserved residue arginine-15 is required for the Ca2+-dependent properties of the gamma-carboxyglutamic acid domain of human anticoagulation protein C and activated protein C.

Authors:  A Thariath; F J Castellino
Journal:  Biochem J       Date:  1997-02-15       Impact factor: 3.857

5.  First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa.

Authors:  D Zhong; K J Smith; J J Birktoft; S P Bajaj
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

6.  Factor IX binding to collagen.

Authors:  D Gailani
Journal:  J Thromb Haemost       Date:  2009-08-19       Impact factor: 5.824

7.  FVIIa as used pharmacologically is not TF dependent in hemophilia B mice.

Authors:  Dengmin Feng; Herbert Whinna; Dougald Monroe; Darrel W Stafford
Journal:  Blood       Date:  2014-01-14       Impact factor: 22.113

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.